Rare Disease Advocacy Groups and Their Significance in Diagnosis, Management, Treatment, and Prevention of Rare Diseases by Bhattacharya, Yashodhara et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Rare Disease Advocacy Groups 
and Their Significance in 
Diagnosis, Management, 
Treatment, and Prevention  
of Rare Diseases
Yashodhara Bhattacharya, Gayatri Iyer,  
Aruna Priya Kamireddy, Subhadra Poornima,  
Keerthi Konda Juturu and Qurratulain Hasan
Abstract
Rare diseases are those diseases that are not seen frequently in a population. There 
are about 7000 rare diseases that have been identified worldwide, and 80% of them are 
caused by genetic changes. Since a small number of individuals are affected with rare 
diseases, most clinicians are not aware of such diseases, and thus, they remain undiag-
nosed and untreated. Awareness regarding such diseases is essential to train clinicians to 
diagnose individuals affected with these disorders and to develop National/International 
Registries, which will serve to give information about the disease prevalence, its natural 
course, treatment, and management options available, to the medical fraternity. Patient 
advocacy groups play a remarkable and unique role in forming the collective voice of 
individuals living with rare diseases. They help in the identification, diagnosis, manage-
ment, treatment, and prevention of such diseases. Advocacy Groups form collaborative 
partnerships with scientists studying such rare diseases, clinicians managing these 
diseases, pharmaceutical companies developing drugs, and Government officials over-
seeing and policy makers implementing medical regulatory processes. Thus, advocacy 
groups play a key role in helping patients and families with rare diseases.
Keywords: rare disease, patient advocacy group, rare disease registry, diagnosis, 
management, treatment
1. Introduction
A rare disease is so called because its frequency in any given population is very 
low [1]. There are about 7000 rare diseases that have been discovered, and more are 
being described in medical literature. Rare diseases have different causes, and about 
80% of them have a genetic basis that could be chromosomal or genomic [2]. Rare 
diseases also include certain rare infections, cancers, and even autoimmune disor-




• The total number of people affected by the disease in that country
• Prevalence of the disease in that country
• Non-availability of treatment for the disease in that country
The USA defines a rare disease as a condition that affects less than 200,000 
people. The definition of rare diseases as is defined in the USA was coined in the 
Congress during the Orphan Drug Act of 1983. Such diseases also came to be known 
as Orphan Diseases as drug companies were indifferent to adopting the research 
and manufacture of novel drugs for their treatment [2, 3]. The World Health 
Organization defines a rare disease as a disease with a frequency of less than 6.5–10 
per 10,000 people. In Europe, it is defined as a disease seen in less than 5 of every 
10,000 people, while in Australia, it is taken as one in 10,000 individuals, and in 
India, it is taken as one in 5000 individuals [4, 5].
A rare disease in isolation may affect a small population because of which 
clinicians are not aware of the disease and their symptoms, hence such  
individuals remain undiagnosed and untreated [1, 6, 7]. Although individu-
ally these disorders are rare, when taken together the people affected with rare 
diseases constitute a large population of the country. Such diseases are debilitat-
ing and without a proper diagnosis may cause gross morbidity and mortality, 
thereby posing a challenge to the healthcare system of the country [8]. A rare 
disease has an adverse impact on the everyday lives of the whole family and 
their care givers [9–12]. The cost of treatment/management is high and causes 
considerable financial burden to the individuals and their families [8, 11, 12], 
as there is a lack of Government policies regarding this aspect, hindering their 
treatment.
2. Advocacy groups
Since several rare diseases are being diagnosed and brought into light, it is 
required that more time and effort should go into research for understanding 
and preventing such diseases. A remarkable and unique aspect of rare disease 
treatment and management is the evolving role of advocacy groups and their 
collaborative partnerships with scientists studying such diseases, pharmaceuti-
cal companies developing drugs, and Government officials and policy makers 
overseeing medical research and health care [3, 6]. Rare disease advocacy 
groups have played a vital role over the years in the adoption of public policies, 
relocation of available research funding, and other factors affecting the research 
for rare diseases [1, 7]. In most settings, the rare disease advocacy groups 
are created by the family members of the affected individuals. They are the 
ones who look into the formation of public policies, help fast-track treatment 
approvals by regulatory bodies, and facilitate the welfare of individuals and 
their care givers.
The National Organization for Rare Disorders (NORD) in the USA was one of 
the first advocacy groups to be formed, followed by Rare Diseases International, 
which is a global alliance of patients with rare diseases across various nationali-
ties and is dedicated for supporting treatment and formulating policies for rare 
disorders. Apart from these, patient advocacy groups have been formed all over 
the world, which individually or in alliance help to alleviate the various problems 
faced by individuals with rare diseases and to pressurize companies and countries to 
provide life-saving drugs and at a reasonable cost.
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3. Patient advocacy groups in India
There are many patient advocacy groups currently active in India. The Pompe 
Foundation started by Mr. Prasanna Shirol in 2008 and caters to individuals 
and families affected with Lysosomal Storage Disorders. The Metabolic Errors 
and Rare Diseases Organization of India (MERD), founded by Mr. Vikas Bhat, 
promotes awareness regarding Inborn Errors of Metabolism and newborn screen-
ing. Both these organizations have been founded by parents having an affected 
child. There are a few other advocacy groups for Spinal Muscular Atrophy (SMA), 
Spino-Cerebellar Ataxia (SCA), Duchenne Muscular Dystrophy (DMD), and 
Osteogenesis Imperfecta. Twenty-five such organizations together joined hands to 
form the Organization for Rare Diseases India (ORDI), which is actively involved 
in helping patients and their families through the involvement of NGOs. These 
advocacy groups, however, need to be better organized, so that they can obtain and 
disseminate information about diseases, diagnostics, and treatment avenues to the 
affected families.
India has a huge diversity in the kind of rare diseases seen in different states, 
which can be attributed to certain cultural practices such as consanguinity in South 
India and endogamy in the North [13]. Based on the data from these organizations, 
a Rare Disease Registry has been initiated. This has helped in re-classifying rare 
diseases based on their prevalence in different states. Diseases like β-thalassemia 
are more prevalent in Punjab, Gujarat, West Bengal, Odisha, and Andhra Pradesh 
but are rare in other states [14, 15]; hence, they cannot be classified under rare 
diseases in these states. Similarly, house-to-house survey carried out by Molecular 
Diagnostics, Counseling, Care and Research Center (MDCRC) Coimbatore esti-
mates that the prevalence of Duchenne Muscular Dystrophy in Tamil Nadu is high 
and cannot come under a rare disorder in that state [16]. Gradually, such data need 
to be combined, so that advocacy groups can focus their efforts on rare diseases and 
would help in developing a comprehensive and factual National registry, which 
would further aid in framing the National Policy for Rare Diseases [17, 18].
4. Multi-specialty hospital-based advocacy group
In this chapter, we would like to highlight our study that was to evaluate the 
feasibility of initiating an advocacy group for rare diseases in a multi-specialty 
hospital setting with the support of the Department of Genetics and Molecular 
Medicine. The genetic counselors were instrumental in liaising between different 
departments such as pediatrics, nephrology, neurology, orthopedics, and oncology 
for the identification of patients with suspected rare disease. Around 200 such 
patients were identified during the period of April 2016 to April 2019. The patient 
families were encouraged to register with the advocacy group, which would support 
and follow-up the patient and their families and provide the necessary management 
and treatment options as required.
Patients evaluated were identified and categorized based on age into the pedi-
atric and the adult age group. About 63% of the patients were in the pediatric age 
group, and the remaining 37% were in the adult age group.
4.1 Rare disease advocacy group at Kamineni Hospital
To cater to patients affected with such diverse diseases, the first hospital-based 
advocacy group was created at Kamineni Hospital, a multi-specialty hospital 
located in the cosmopolitan city of Hyderabad in South India. It was named Maitri, 
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which originates from the Sanskrit word meaning “friendship.” Maitri looks into the 
collective interests of individuals with rare diseases. The rare disease community 
is often denied the most basic of rights. Society is ill-equipped to understand the 
cause and gravity of the diseases. This often leads to a number of psychological 
problems. A diagnosis is important to understand a disease, its progression, symp-
toms, possible treatment options, and also for its prevention in future generations. 
Most individuals can lead a normal life. However, due to the lack of awareness, such 
individuals are not allowed to do so. People in general lack the sensitivity to accept 
and work alongside individuals suffering from such diseases. Maitri aims to change 
this scenario by raising awareness among clinicians, the general public, in schools, 
and colleges. It also looks into extended family screening and counseling for making 
informed reproductive decisions.
4.1.1  MAITRI (bond of friendship) – Kamineni Hospital’s rare disease advocacy 
group
The Department of Genetics and Molecular Medicine along with its team of 
genetic counselors created Maitri to collectively address the various problems faced 
by individuals suffering from rare diseases.
Objectives of Maitri:
• To raise awareness about rare diseases among healthcare professionals, general 
public, and policy makers
• To evaluate and diagnose an individual with a suspected rare disease
• To identify individuals with rare diseases at Kamineni Hospital and include 
them in the Kamineni Rare Disease Registry
• To counsel the patient, parents, and family about the disease and its prognosis, 
management, and treatment options (if any)
• To identify individuals in the extended family at risk of having the disease
• To create self-help groups of individuals with similar symptoms/problems for 
discussion and possible management options
• To help cope with psychosocial issues
• To conduct parental/family group sessions about the different rare diseases and 
on the various psychosocial problems faced by them
• To involve teachers from the pre-school level, school, special schools, and 
college level in the advocacy group. To create awareness among them and other 
teaching staff about dealing with an individual affected with rare diseases to 
integrate individuals into the mainstream schools/colleges and allow them to 
lead a normal life.
4.2 General workflow of Maitri
Every patient visiting the Department of Genetics and Molecular Medicine was 
evaluated in two or more sessions as a part of primary evaluation (Figure 1).
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Patients were segregated based on the following age groups and advised accordingly.
a. Pediatric age group:
Age 0–5 years: Parental discussions on symptom management, addressing vari-
ous needs of the child. Refer for clinical follow-up and psychological evaluation of 
the child prior to school admission.
Age 6–15 years: Addressing psychological needs of the patient. Group discussion 
programs with teachers, parents, and other healthcare professionals. Address issues 
faced at school and mitigate it.
b. Adult age group:
Age 16–22 years: Patient and parental psychological consultation to address vari-
ous psychosocial issues. One-on-one patient meetings with geneticist and psycholo-
gist to address puberty-related problems. Reproductive counseling is also given.
Age 23–40 years: Pre-marital, pre-pregnancy genetic counseling, group sessions 
with other patients and their family to address common issues. Refer for clinical 
follow-up if needed.
Age > 40 years: Group sessions for patient and families for discussion of symp-
toms, their management, possible treatment options, and psychosocial problems 
faced due to the condition. Pre-symptomatic genetic testing and subsequent advice 
for children of individuals affected with rare diseases.
• Individual patients requiring vocational, behavioral, or occupational therapy 
are referred for the same
Figure 1. 
Flowchart for the working of Maitri.
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The importance of a rare disease advocacy group at the National and 
International level has been established by many esteemed clinicians, geneticists, 
and social workers. However, such groups at a hospital setting are important in a 
country like India, where there are limited electronic medical records, and there is 
huge literary and financial disparity in the population, such advocacy groups may 
contribute to maintaining crucial information for providing better healthcare and 
support to patient families.
5. Conclusion
Hospital-based Rare Disease Advocacy Groups like Maitri are crucial in a 
number of ways they help in establishing prevalence of rare disorders through the 
hospital-based registries. They promote awareness, so that every affected individual 
may be tested for a diagnosis. Such advocacy groups help bring together families 
with same, similar, or even different rare diseases, so that they can help and sup-
port each other. Groups like Maitri also perform a very important role in extended 
family screening, wherein they identify individuals at risk of developing the 
disorder and are counseled regarding appropriate testing and preventive measures. 
It also encourages reproductive genetic counseling for the families with an affected 
individual, which would help prevent the disorder in the future generations.
Advocacy groups along with policy makers are instrumental in creating public 
awareness about such diseases. Increase in awareness would make their prevention 
a public health concern, thus making it mandatory to have definitive screening and 
preventive strategies in the country. Not only advocacy groups are important for 
the support of individual families, but they also play a role in mass awareness and 
prevention of rare diseases.
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